ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Abstracts From AACR Annual Meeting

May 21, 1976

In Brief: Bioassay Prime Contract Renewed For Four Years, $34.2 Million; Canellos Quits As Clinical Director

June 20, 1975

Faulty Estimates Led NCI To Overstate Black-White Cancer Disparity In Atlanta

September 20, 2002

ASCO Entering Prime Of Life

May 31, 1991

USC Opts for Its own IL-2 Protocol, Shuns NCI Trial

May 8, 1987

In Brief: Schmidt Has Doubts About Community Saturation Program; Diane Fink Wins Gerard Lambert Award

July 25, 1975